Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Trillium Therapeutic (TRIL)

Trillium Therapeutic (TRIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 740,040
  • Shares Outstanding, K 84,576
  • Annual Sales, $ 120 K
  • Annual Income, $ -41,620 K
  • 60-Month Beta 2.07
  • Price/Sales 6,077.19
  • Price/Cash Flow N/A
  • Price/Book 11.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.75 +52.17%
on 07/30/20
9.09 -3.74%
on 08/14/20
+1.39 (+18.89%)
since 07/14/20
3-Month
5.66 +54.59%
on 05/15/20
9.66 -9.42%
on 06/22/20
+2.86 (+48.56%)
since 05/14/20
52-Week
0.24 +3,538.25%
on 10/31/19
9.66 -9.42%
on 06/22/20
+8.50 (+3,448.26%)
since 08/14/19

Most Recent Stories

More News
Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results

-- TTI-621 study has progressed to the 2.0 mg/kg dosing level

TRIL : 8.75 (-1.80%)
4 Best-Performing Small-cap Biotechnology Stocks

Biotech stocks have been one of the strongest sectors since the coronavirus started impacting financial markets.  Here are 4 of the best-performing small-cap biotech stocks in 2020. Biotech stocks...

AKBA : 10.53 (-0.94%)
IBB : 133.36 (-0.48%)
MRSN : 18.58 (+1.59%)
VXRT : 9.14 (+0.55%)
TRIL : 8.75 (-1.80%)
Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, provided an update today...

TRIL : 8.75 (-1.80%)
Is the Options Market Predicting a Spike in Trillium Therapeutics (TRIL) Stock?

Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.

TRIL : 8.75 (-1.80%)
Thinking about buying stock in Party City, Altimmune, Trillium Therapeutics, Renren Inc, or Delta Air Lines?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRTY, ALT, TRIL, RENN, and DAL.

DAL : 28.95 (+0.87%)
PRTY : 2.60 (+28.08%)
RENN : 2.49 (+0.81%)
TRIL : 8.75 (-1.80%)
Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

-- Dosing has progressed through first five cohorts up to 4 mg/kg dose level

TRIL : 8.75 (-1.80%)
Are Options Traders Betting on a Big Move in Trillium (TRIL) Stock?

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

TRIL : 8.75 (-1.80%)
Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial...

TRIL : 8.75 (-1.80%)
Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its...

TRIL : 8.75 (-1.80%)
Trillium Therapeutics Announces "At-The-Market" Equity Program

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it...

TRIL : 8.75 (-1.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade TRIL with:

Business Summary

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin...

See More

Key Turning Points

2nd Resistance Point 9.36
1st Resistance Point 9.05
Last Price 8.75
1st Support Level 8.48
2nd Support Level 8.22

See More

52-Week High 9.66
Last Price 8.75
Fibonacci 61.8% 6.06
Fibonacci 50% 4.95
Fibonacci 38.2% 3.84
52-Week Low 0.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar